192869-56-0

Basic information

• Product Name: Benzonitrile, 4-Methoxy-2-nitro-5-(phenylMethoxy)-
• Synonyms: Benzonitrile, 4-Methoxy-2-nitro-5-(phenylMethoxy)-;5-(benzyloxy)-4-methoxy-2-nitrobenzonitrile
• CAS NO: 192869-56-0
• Molecular Formula: C₁₅H₁₂N₂O₄
• Molecular Weight: 284.26678
• EINECS: -0
• Mol File: 192869-56-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzonitrile, 4-Methoxy-2-nitro-5-(phenylMethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-Methoxy-2-nitro-5-(phenylMethoxy)-(192869-56-0)
• EPA Substance Registry System: Benzonitrile, 4-Methoxy-2-nitro-5-(phenylMethoxy)-(192869-56-0)

Safety Data

• Hazardous Substances Data: 192869-56-0(Hazardous Substances Data)

Upstream product

• 52805-46-6 2-methoxy-5-cyanophenol 
• 100-39-0 benzyl bromide 
• 621-59-0 isovanillin 
• 52805-37-5 3-benzyloxy-4-methoxybenzonitrile 

Downstream Products

• 192869-57-1 2-amino-5-benzyloxy-4-methoxybenzonitrile 
• 913819-12-2 6-(benzyloxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine 

Relevant articles and documents

4-anilinoquinazoline derivative and albumin conjugates thereof

a pharmaceutical composition for preventing, treating, or ameliorating one or more symptoms of a malignant tumor associated with EGFR mutation and/or K-RAS mutation is provided. The pharmaceutical composition includes a 4-anilinoquinazoline derivative having a formula (I) where A is iodine when m is 1 and n is zero, or A is albumin when m is an integral ranging from 1 to 7 and n is 1.

A method for preparing gefitinib, a tyrosine kinase inhibitor

The invention discloses a method for preparing gefitinib that is a tyrosine kinase inhibitor, and belongs to the fields of medicines and fine chemical engineering. The method is a novel preparation scheme, and can prepare a target compound meeting requirements no matter from which intermediate. The method has advantages of short steps, simple reaction operation, high safety and reliability, a highyield, a low cost, high product purity, low pollution, simple operation, and the like.

Synthesis and biological assay of erlotinib analogues and BSA-conjugated erlotinib analogue

A series of erlotinib analogues that have structural modification at 6,7-alkoxyl positions is efficiently synthesized. The in vitro anti-tumor activity of synthesized compounds is studied in two non-small cell lung cancer (NSCLC) cell lines (A549 and H1975). Among the synthesized compounds, the iodo compound 6 (ETN-6) exhibits higher anti-cancer activity compared to erlotinib. An efficient method is developed for the conjugation of erlotinib analogue-4, alcohol compound, with protein, bovine serum albumin (BSA), via succinic acid linker. The in vitro anti-tumor activity of the protein attached erlotinib analogue, 8 (ETN-4-Suc-BSA), showed stronger inhibitory activity in both A549 and H1975 NSCLC cell lines.

PROCESS FOR PREPARING QUINAZOLINE DERIVATIVE

A concise, efficient and cost-and time-saving process for the preparation of a quinazoline derivative of formula (A) given below: which is an intermediate for making gefitinib or gefitinib itself, comprising reacting a compound of formula (B): with 3-chloro-4-fluoroaniline (VI) in the presence of a N,N-dialkyl formamide acetal, a Bronsted acid catalyst, and a solvent in a one-pot reaction.

Optimization of gefitinib analogues with potent anticancer activity

The interactions of gefitinib (Iressa) in EGFR are hydrogen bonding and van der Waals forces through quinazoline and aniline rings. However the morpholino group of gefitinib is poorly ordered due to its weak electron density. A series of novel piperazino analogues of gefitinib where morpholino group substituted with various piperazino groups were designed and synthesized. Most of them indicated significant anti-cancer activities against human cancer cell lines. In particular, compounds 52-54 showed excellent potency against cancer cells. Convergent synthetic approach has been developed for the synthesis of gefitinib intermediate which can lead to gefitinib as well as numerous analogues.

Quinoline and quinazoline compounds useful in therapy

Compounds of formula I, wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents an aryl group or a heteroaryl group, optionally substituted by C1-4 alkyl or SO2

Quinolines and quinazolines useful in therapy

Compounds of formula I, wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 and R3 independently represent H or C1-6 alkoxy (which is optionally substituted); R4 represents a 4-, 5-, 6- or 7-membered heterocyclic rin

Quinoline and quinazoline compounds useful in therapy

PCT No. PCT/EP96/05609 Sec. 371 Date Jun. 17, 1998 Sec. 102(e) Date Jun. 17, 1998 PCT Filed Dec. 5, 1996 PCT Pub. No. WO97/23462 PCT Pub. Date Jul. 3, 1997The invention provides compounds of formula (I), wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents H or C1-6 alkoxy optionally substituted by one or more fluorine atoms; R3 represents one or more groups independently selected from H, halogen, C1-4 alkoxy and CF3; in addition, R2 and one R3 group may together represent -OCH2-, the methylene group being attached to the ortho-position of the pendant phenyl ring; R4 represents a 4-, 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent or represents a cyclic group or an open chain group; and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of inter alia benign prostatic hyperplasia.